Vaxxinity, Inc. (VAXX)
USD 0.05
(200.0%)
USD 0.05
(200.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -56.05 Thousand USD | 99.92% |
| 2022 | -74.29 Million USD | 41.08% |
| 2021 | -135.23 Million USD | -232.11% |
| 2020 | -31.56 Million USD | -174.84% |
| 2019 | -13.58 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q3 | -12.26 Million USD | 7.93% |
| 2023 Q2 | -13.32 Million USD | 24.54% |
| 2023 Q1 | -17.65 Million USD | 10.15% |
| 2023 FY | - USD | 23.26% |
| 2023 Q4 | -11.19 Million USD | 8.75% |
| 2022 Q4 | -19.65 Million USD | -4.5% |
| 2022 Q3 | -18.8 Million USD | -12.22% |
| 2022 Q2 | -16.75 Million USD | 6.0% |
| 2022 Q1 | -17.82 Million USD | 60.39% |
| 2022 FY | - USD | 41.08% |
| 2021 Q4 | -45 Million USD | -50.45% |
| 2021 Q3 | -29.91 Million USD | -12.82% |
| 2021 Q2 | -26.51 Million USD | -17.1% |
| 2021 FY | - USD | -232.11% |
| 2021 Q1 | -22.64 Million USD | -91.05% |
| 2020 Q2 | -6.84 Million USD | -271583.88% |
| 2020 FY | - USD | -174.84% |
| 2020 Q1 | -2518.00 USD | 0.0% |
| 2020 Q4 | -11.85 Million USD | 22.24% |
| 2020 Q3 | -15.24 Million USD | -122.79% |
| 2019 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | 87.469% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 99.81% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 99.951% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 99.644% |
| Better Therapeutics, Inc. | -38.26 Million USD | 99.854% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 99.854% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 99.687% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 99.834% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 99.832% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 99.947% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | 93.864% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 99.827% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 99.88% |
| Innovation1 Biotech Inc. | -5.68 Million USD | 99.014% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 99.656% |
| Molecular Templates, Inc. | 1.43 Million USD | 103.92% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | 99.596% |
| NexImmune, Inc. | -28.16 Million USD | 99.801% |
| Orgenesis Inc. | -60.71 Million USD | 99.908% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 99.891% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | 23.653% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 99.653% |
| Scopus BioPharma Inc. | -11.71 Million USD | 99.521% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 99.99% |
| Statera Biopharma, Inc. | 38.93 Million USD | 100.144% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 99.186% |
| Trevena, Inc. | -35.28 Million USD | 99.841% |
| Vaccinex, Inc. | -19.74 Million USD | 99.716% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | 94.646% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 99.88% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 99.228% |